PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Allergan and CMO At Altheos to Speak At Ocular Drug Discovery Conference February 27-28 in Las Vegas - David Woodward, Senior Director of Biological Sciences at Allergan and Barbara Wirostko, Chief Medical Officer at Altheos will give a joint featured presentation at the 4th Ocular Diseases and Drug Discovery Conference
Allergan and CMO At Altheos to Speak At Ocular Drug Discovery Conference February 27-28 in Las Vegas

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2012/01/01 - David Woodward, Senior Director of Biological Sciences at Allergan and Barbara Wirostko, Chief Medical Officer at Altheos will give a joint featured presentation at the 4th Ocular Diseases and Drug Discovery Conference.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

David Woodward, Senior Director of Biological Sciences at Allergan and Barbara Wirostko, Chief Medical Officer at Altheos will give a joint featured presentation entitled “Critical Success Factors in Approving Ophthalmic Drugs: Prostaglandins for Glaucoma/OHT as a Case Study: What Next?” at the 4th Ocular Diseases and Drug Discovery Conference taking place on February 27-28, 2012 in Las Vegas, NV.

The success factors for successful drug discovery may be reflected by the past and present scenario for anti-glaucoma prostanoids. The first in class, latanoprost became a successful drug despite a high incidence of iridial & periocular hyperpigmentation, ocular surface hyperemia, lash lengthening and even occasional and rechallenge episodes of inflammation (CME). Although they were approved, Pharmacia/ Pfizer had to collect 5 year safety data to support the ocular safety and determine the “long” term outcome of the iridial hyperemia.

More recently prostanoid EP2 receptor agonists have taken center stage. These do not appear to have advanced beyond clinical efficacy studies to date. In looking at the next IOP lowering agent, the hurdle will be high not only for ocular and systemic safety but also for efficacy. Safety has always been but is even more so paramount to the approval process.

David Woodward is a Senior Director at Allergan. His main research foci are ocular diseases, hair growth, and inflammatory diseases. He is the author of 165 peer reviewed papers and invited reviews. He is inventor of 83 published patents, with numerous other applications in process. He was appointed as an ARVO fellow in 2010 and was awarded the inaugural Allergan Distinguished Scientist Award.

Barbara Wirostko, a board certified Ophthalmologist, is Chief Medical Officer of Altheos, a biotech company developing a ROCK inhibitor for glaucoma. She maintains an academic research and clinical affiliation with the University of Utah, Moran Eye Center, as a Clinical Adjunct Associate Professor in Ophthalmology. She serves on the Grant Review Working Group for CIRM, California Institute for Regenerative Medicine and is on the editorial board of Acta Ophthalmologic and World Journal of Ophthalmology. She consults for several companies including SKS, Merck, Macuclear and iVeena. Prior to her most recent position, she was Senior Medical Director within the Clinical Development and Medical Affairs division at Pfizer in NY. She oversaw the development of pipeline glaucoma strategy and global medical / clinical programs for Xalabrands. She was the team lead for a successful Phase 3 regulatory filing to the European regulatory agency (EMA) for a pediatric glaucoma indication.

GTC’s 4th Ocular Diseases and Drug Discovery Conference will bring together a 50-50 mix of academic and high-level industry experts from leading affiliations to discuss and collaborate on the latest research and discovery, safety assessment, and development of drugs for combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, uveitis and other eye diseases. Leading scientists and researchers include key experts such as M. (Ken) Kengatharan, Barbara Wirostko, David Woodward, Henry F. Edelhauser, Ken Mandell, Bala Ambati, etc. The last annual conference was well attended with representation from key R&D professionals from GSK, Pfizer, B&L, Allergan and Alcon and this year is showing promise of being even bigger and better.

This conference is part of the Targets and Strategies in Drug Discovery Summit and runs concurrently with three other tracks:

1) 3rd Cancer Targets and Therapeutics;
2) Oncology Partnering & Deal-Making Conference;
3) 2nd Ubiquitin Research and Drug Discovery.

For more information, please visit GTCbio.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Allergan and CMO At Altheos to Speak At Ocular Drug Discovery Conference February 27-28 in Las Vegas

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)